ESMO Congress | Conference

Atezolizumab Improves Survival in High PD-L1 Expressing NSCLC

September 27th 2019

Atezolizumab (Tecentriq) monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment of certain patients with wild-type non–small cell lung cancer.

Pemigatinib Active as Second-Line Treatment for FGFR2+ Cholangiocarcinoma

September 27th 2019

More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.

Apalutamide Linked to OS Benefit in Nonmetastatic CRPC

September 27th 2019

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

Dr. Choueiri on the Impact of the JAVELIN Renal 101 Findings in RCC

October 25th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of the JAVELIN Renal 100 trial on the treatment landscape of renal cell carcinoma.

Dr. Mehanna on the Updated Staging System for HPV+ Head and Neck Cancer

October 25th 2018

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the new staging system for patients with HPV-positive head and neck cancer.

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

October 23rd 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Dr. Schmid Discusses the Findings of the IMpassion130 Trial in TNBC

October 23rd 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

Frontline Alectinib Outperforms Crizotinib in Asian Patients With ALK+ NSCLC

October 23rd 2018

Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC

October 22nd 2018

The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.

Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer

October 22nd 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

October 22nd 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Cisplatin Remains Standard for Low-Risk HPV+ Oropharyngeal Cancer

October 22nd 2018

Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22nd 2018

Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.

Trifluridine/Tipiracil Extends Survival in Heavily Pretreated Gastric/GEJ Cancer

October 22nd 2018

Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.

Pembrolizumab Improves OS, but Not PFS and ORR in Frontline HNSCC

October 22nd 2018

Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.

Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC

October 22nd 2018

The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.

Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC

October 22nd 2018

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer

October 22nd 2018

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.